Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

The Brigham and Women's Hospital Inc., Massachusetts General Hospital and UCL Business Ltd. have jointly patented new benzo[c][l,2,5]thiadiazolyl compounds and radiolabeled derivatives targeting ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

It’s been a minute since Lifehacker looked at the slang of Generation Z—long enough that Generation Alpha has had time to develop and spread some of its own special buzzwords and jargon.

Mitochondria are critical for cellular homeostasis, regulating bioenergetics, redox balance, Ca2+ signaling, and cell death. Mitochondrial Ca2+ ...

Although there is no cure for Parkinson's disease, medications and surgery can help relieve some of the symptoms. Alpha-synuclein is a protein in the human brain that’s involved in the release of ...

Manganese has been previously shown to bind with the protein alpha-synuclein, causing it to misfold and accumulate in the brain. Using the fruit fly Drosophila, researchers developed a model that ...

This ATP decline may result in α-synuclein accumulation, autophagy-lysosomal system impairment, neuronal network breakdown and accelerated neurodegeneration. We propose an “ATP Supply–Demand Mismatch ...

In a paper published last year, an international team of scientists describes how the two proteins work together to help harmful alpha-synuclein protein clumps get into brain cells. "Now that we know ...